دورية أكاديمية
أعرض في EDS

Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.

التفاصيل البيبلوغرافية
العنوان: Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
المؤلفون: Bravo MI; Bioscience Research Group, Grifols, Barcelona, Spain., Pérez A; Bioscience Research Group, Grifols, Barcelona, Spain., Raventós A; Bioscience Research Group, Grifols, Barcelona, Spain., Grancha S; Bioscience Research Group, Grifols, Barcelona, Spain., Jorquera JI; Bioscience Research Group, Grifols, Barcelona, Spain., Butta NV; Thrombosis and Haemostasis Unit - IdiPAZ, University Hospital La Paz, Madrid, Spain., Álvarez-Román MT; Thrombosis and Haemostasis Unit - IdiPAZ, University Hospital La Paz, Madrid, Spain., Costa M; Bioscience Research Group, Grifols, Barcelona, Spain., Willis T; Bioscience Research Group, Grifols, Raleigh, North Carolina, USA., Jiménez-Yuste V; Thrombosis and Haemostasis Unit - IdiPAZ, University Hospital La Paz, Madrid, Spain.; Medicine Department, Autonoma University of Madrid, Madrid, Spain.
المصدر: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2022 Sep; Vol. 28 (5), pp. 737-744. Date of Electronic Publication: 2022 Jun 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Blackwell Science Country of Publication: England NLM ID: 9442916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2516 (Electronic) Linking ISSN: 13518216 NLM ISO Abbreviation: Haemophilia Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Osney Mead, Oxford, UK : Blackwell Science, [1994-
مواضيع طبية MeSH: Factor VIII*/administration & dosage , Factor VIII*/immunology , Factor VIII*/isolation & purification , Hemophilia A*/therapy , von Willebrand Factor*/administration & dosage , von Willebrand Factor*/isolation & purification, Animals ; Disease Models, Animal ; Immunoglobulin G/immunology ; Mice ; Recombinant Proteins/administration & dosage
مستخلص: Introduction: Presence of von Willebrand factor (VWF) in FVIII concentrates offers protection against neutralizing inhibitors in haemophilia A (HA). Whether this protection is more evident in plasma-derived (pd) FVIII/VWF or recombinant (r) FVIII concentrates remains controversial.
Aim: We investigated the protection exerted by VWF against FVIII inhibitors in an in vivo mouse model of HA exposed to pdFVIII/VWF or to various rFVIII concentrates.
Methods: Haemophilia A mice received the different FVIII concentrates after administration of vehicle or an inhibitory IgG purified from a commercial pool of HA plasma with inhibitors and FVIII:C recoveries were measured. Furthermore, using a novel clinically oriented ex vivo approach, Bethesda inhibitory activities (BU) of a commercial pool of HA plasma with inhibitors were assessed using normal plasma, or plasma from severe HA patients, without inhibitors, after treatment with the same concentrates.
Results: in vivo studies showed that pdFVIII/VWF offers markedly higher protection against inhibitors when compared with any of the FVIII products without VWF. More importantly, in the ex vivo studies, plasma from patients treated with pdFVIII/VWF showed higher protection against inhibitors (P values ranging .05-.001) in comparison with that observed in plasma from patients who received FVIII products without VWF, regardless of the type of product evaluated.
Conclusion: Data indicate that FVIII+VWF complexes assembled in the circulation after rFVIII infusion are not equivalent to the naturally formed complex in pdFVIII/VWF. Therefore, rFVIII infused into HA patients with inhibitors would be less protected by VWF than the FVIII in pdFVIII/VWF concentrates.
(© 2022 The Authors. Haemophilia published by John Wiley & Sons Ltd.)
References: Haemophilia. 1996 Apr;2(2):95-9. (PMID: 27214015)
Blood Rev. 2017 Sep;31(5):339-347. (PMID: 28716211)
J Thromb Haemost. 2011 Jul;9 Suppl 1:130-43. (PMID: 21781248)
Methods Mol Biol. 2013;992:321-33. (PMID: 23546724)
Thromb Haemost. 1999 Feb;81(2):240-4. (PMID: 10063999)
Haematologica. 2013 Oct;98(10):1650-5. (PMID: 23716558)
PLoS One. 2015 Oct 16;10(10):e0140740. (PMID: 26473492)
Haemophilia. 2014 Nov;20(6):905-11. (PMID: 25156825)
Haemophilia. 2012 Nov;18(6):982-9. (PMID: 22646163)
Blood. 2014 Nov 27;124(23):3398-408. (PMID: 25253771)
Haemophilia. 2004 Sep;10(5):459-69. (PMID: 15357771)
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7405-9. (PMID: 1908096)
J Thromb Haemost. 2004 Jun;2(6):861-2. (PMID: 15140115)
Blood. 2006 Jan 1;107(1):46-51. (PMID: 16166584)
Haematologica. 2020 Mar;105(3):545-553. (PMID: 32060150)
Haemophilia. 2016 Jul;22(4):e341-4. (PMID: 27354216)
J Biol Chem. 1994 Aug 5;269(31):20095-102. (PMID: 8051097)
Thromb Haemost. 1999 Feb;81(2):306-11. (PMID: 10064011)
Haemophilia. 2001 Jul;7(4):369-74. (PMID: 11442641)
N Engl J Med. 2016 May 26;374(21):2054-64. (PMID: 27223147)
J Biol Chem. 1991 Jan 15;266(2):740-6. (PMID: 1898735)
Blood. 1995 Jun 1;85(11):3150-7. (PMID: 7756647)
N Engl J Med. 2013 Jan 17;368(3):231-9. (PMID: 23323899)
Eur J Biochem. 1990 Dec 12;194(2):491-8. (PMID: 2125268)
Am J Hematol. 2007 Jun;82(6):460-2. (PMID: 17211843)
J Thromb Haemost. 2012 May;10(5):781-90. (PMID: 22452823)
Haemophilia. 2022 Sep;28(5):737-744. (PMID: 35654086)
Thromb Haemost. 2015 May;113(5):968-75. (PMID: 25567324)
Blood. 2015 Mar 26;125(13):2019-28. (PMID: 25712991)
J Thromb Haemost. 2012 Nov;10(11):2328-37. (PMID: 22908929)
Haemophilia. 2011 Jul;17(4):709-10. (PMID: 21299741)
Hum Gene Ther. 2000 Apr 10;11(6):881-94. (PMID: 10779165)
Haemophilia. 2010 Jan;16(1):e190-201. (PMID: 19845772)
Blood. 2017 Jun 15;129(24):3147-3154. (PMID: 28432221)
Front Med (Lausanne). 2019 Dec 03;6:261. (PMID: 31850352)
Haemophilia. 2012 Jul;18(4):639-46. (PMID: 22221819)
Haemophilia. 2014 Sep;20 Suppl 6:2-16. (PMID: 24975700)
Br J Haematol. 2020 Apr;189(1):39-53. (PMID: 32064603)
معلومات مُعتمدة: Grifols
فهرسة مساهمة: Keywords: FVIII inhibitors; FVIIInull E16 Knockout mice; haemophilia A patients; haemophilia A treatment; plasma-derived FVIII; recombinant FVIII; von Willebrand factor
المشرفين على المادة: 0 (Immunoglobulin G)
0 (Recombinant Proteins)
0 (von Willebrand Factor)
9001-27-8 (Factor VIII)
تواريخ الأحداث: Date Created: 20220602 Date Completed: 20220913 Latest Revision: 20221015
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9545517
DOI: 10.1111/hae.14589
PMID: 35654086
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2516
DOI:10.1111/hae.14589